10/07/2019 – Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit.
Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD) Grant program to further support the Phase II clinical study. Privo Technologies is one of 12 institutions in the US to have received this grant in 2019.
12/02/2018 – MIT Selects Privo Technologies To Showcase the Company’s Groundbreaking Cancer Therapy in Japan and Korea.
Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its nano-engineered platform technology and its product PRV111 for oral cancer at two major events in Asia. In January 2019, Privo will proudly represent the kind of innovation and entrepreneurship Massachusetts Institute of Technology (MIT) enables when CEO Manijeh Goldberg will introduce Privo’s research and products at the 2019 MIT Japan Conference in Tokyo, as well as at the Korea Symposium in Seoul, South Korea. Privo will welcome this opportunity to introduce its groundbreaking cancer therapy to the Asian market and establish collaborative partnerships with industry leaders in Japan as well as Korea.
11/12/2018 – Privo Technologies receives $3M Bridge Award from the National Cancer Institute (NCI).
Privo Technologies has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute to support Privo’s clinical trial for it’s nanotechnology-based treatment of oral cancer. View Full Article
10/24/2018 – Privo Technologies begins FDA Approved Clinical Trials.
Privo Technologies was granted the green light from the FDA and several hospitals this summer to begin patient recruitment for a prospective clinical trial targeting early stage oral cavity. View Full Article
01/10/2017 – Honored at the White House Privo Technologies receives the 2016 National Tibbetts Award
Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to the Small Business Innovation Research (SBIR) program. The SBIR program stated “We are proud to recognize your company’s outstanding work that has contributed so greatly to the success of the SBIR program.” Privo would like to congratulate it’s team for their hard work and dedication to the company. On January 10, 2017, Privo’s CEO and Founder, Dr. Manijeh Goldberg, received the honor at the White House during a special awards ceremony. View Full Article.
12/10/2016 – Privo Technologies receives 2015 TechConnect Innovation Award.
Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated in the top 5% of all award applicants. View Full Article
09/13/2016 – Privo receives Commercialization Award from the National Cancer Institute.
Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and would like to thank the National Cancer Institute for funding Privo’s inclusion as part of this conference.
04/01/2016 – National Cancer Institute awards Privo a $2.5M grant to optimize it lead product and prepare for its IND.
03/01/2016 – Privo receives a $2M Award from the National Institute of Dental and Craniofacial Research (NIDCR)
Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
12/10/2015 – Privo Technologies opens new lab facility in Peabody, Ma.
Privo Technologies expands to a new 3000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place, Suite 6B in Peabody, Massachusetts, the new facility consists of two seperate research labs that will be used in it’s continued pursuit of excellence in the field of cancer research. Privo’s new location provides office space and conference rooms to accommodate the company’s continued growth moving forward.
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral cancer treatments to additional patent protection, 7 years of drug exclusivity, and tax credits equal to 50% of research and development costs. Orphan Designation will enable Privo to accelerate the drug development timeline for oral cancer treatment.
08/01/2015 – Privo receives a $220,000 Award from the National Institute of Dental and Craniofacial Research (NIDCR)
Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the company’s drug development activities. We are proud to receive these very competitive awards and honored to be amongst some of the best innovations coming out of the Massachusetts Institute of Technology (MIT).